Celine Verheust
Waver, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance.
Journal: Drug safety
Published: December 22, 2025
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 06, 2023
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
Journal: The Journal of infectious diseases
Published: April 19, 2023
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Journal: Respiratory investigation
Published: June 21, 2022
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Journal: The Journal of infectious diseases
Published: May 27, 2022
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: September 29, 2021
Safety profile of Infanrix hexa - 17 years of GSK's passive post-marketing surveillance.
Journal: Expert review of vaccines
Published: July 31, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026